An interventional study of Xperience™ Advanced Surgical Irrigation and Dilute Povidone-Iodine in Surgical Site Infection, Surgical Complication and Implant Infection, sponsored by University of North Carolina, Chapel Hill. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 202 studies in Surgical Wound Infection with a site in United States — 31 open to participants now, 34 under way, 4 of them phase 3. Surgical Wound Infection · United States.
Among the 202 studies in Surgical Wound Infection with a site in United States, this one is the 85th largest by planned enrollment of the 177 interventional ones that give a count, is one of 7 that started in 2025, is one of 85 with no phase, reaches primary completion later than 27 of the 33 other live ones, and was the 183rd registered.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
Browse Surgical Wound Infection studies →31 of the 202 studies in Surgical Wound Infection with a site in United States are open now. Recruiting first, the newest first:
Montefiore Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Macro Biologics, Inc. · Sites in United States
Ages 18+
Riverside University Health System Medical Center · Sites in United States
Ages 18+ · Women only
Rhode Island Hospital · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 85 Surgical Wound Infection studies recruiting now, 62 (73%) set no upper age limit and 16 (19%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
202 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 15 · Phase 3 33 · Phase 4 39
First in 2002; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 224 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Median enrollment 208 across the 177 interventional studies, 300 across the 23 observational. Of the 144 that completed or were terminated, 78 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 202 have an industry lead sponsor. The 10 most frequent:
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
University of North Carolina, Chapel Hill has 3 studies filed under Surgical Wound Infection — fewer than ten, so there is no comparison to draw.
12 of the studies in Surgical Wound Infection with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06014411Hospital for Special Surgery, New YorkEarly Versus Delayed Bathing of Orthopaedic Surgical Wounds | 2026-12 |
| NCT04773457Boston Children's HospitalNeutrophil Phenotypic Profiling and Surgical Site Infections in Surgical Patients | 2026-12-01 |
| NCT04725916Sean DevittStudying How Outpatient Water affEcts Risks With Drains (SHOWER Study) | 2026-12-15 |
| NCT06378359University of MinnesotaEffectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients | 2026-12-31 |
| NCT07379684Macro Biologics, Inc.A Study of Amicidin-β Topical Solution for Patients With a Contaminated or Infected Surgical or Traumatic Wound or Cutaneous Abscess | 2027-02-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 202 studies in Surgical Wound Infection with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Goal of the Clinical Trial:
The purpose of this clinical trial is to learn whether Xperience™ surgical irrigation solution is more effective than a standard dilute povidone-iodine solution in reducing surgical site infections (SSIs) following implant-based breast reconstruction in female patients, aged 18 and older. It will also assess the safety and overall surgical outcomes when using Xperience™ compared to povidone-iodine.
Main Questions the Study Aims to Answer:
Study Design:
Participants in this study will be randomly assigned to receive either Xperience™ or a dilute povidone-iodine solution during their bilateral implant-based breast reconstruction. Only the research team will know which irrgiation is given- the participant will not know.
Participant Will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Xperience™ Advanced Surgical Irrigation
Device: Dilute Povidone-Iodine
Xperience™ solution will be applied twice during reconstruction procedures: first after achieving hemostasis and second just before implant introduction. The solution will be warmed to body temperature before use. Both tissue expanders/implants and mastectomy pockets will be soaked with Xperience™, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of Xperience™ will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout, and no rinsing will occur post-irrigation. Surgical site closure will follow standard procedures.
5% dilute povidone-iodine solution will be prepared by mixing povidone-iodine solution and normal saline at the appropriate ratio. Both tissue expanders/implants and mastectomy pockets will be soaked with dilute povidone-iodine, using sterile syringes. A 1-minute dwell time with a total volume of 500 mL per mastectomy pocket will be employed, twice. Additionally, 500 mL of dilute povidone-iodine will be applied to implants before insertion, with a 5-minute dwell time. Excess solution will be suctioned throughout. Surgeon discretion will determine rinsing after irrigation. Surgical site closure will follow standard procedures.
Also known as: Dilute Betadine
Rate of Surgical Site Infections
Number of patients diagnosed with surgical site infections as per the diagnostic criteria outlined by the Centers for Disease Control National Healthcare Safety Network's 2024 Breast Surgery (BRST) Surgical Site Infection Criteria.
Time frame: Within 90 days of implant/tissue expander placement, with the day of placement Day 0.
Rate of Implant Explantation
Number of patients who required non-elective implant explantation.
Time frame: Within 90 days of implant/tissue expander placement, with the day of placement Day 0.
Rate of Non-Infectious Post-Surgical Complications
Number of patients who experience the the following, but not limited to, post-surgical complications: * Delayed wound healing (superficial incisional dehiscence requiring serial dressing changes, office debridement and/or operative revision) * Hematoma * Seroma * Tissue expander leak/rupture * Tissue expander/Implant exposure/extrusion
Time frame: Within 90 days of implant/tissue expander placement, with the day of placement Day 0.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.
Of 202 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 47. This study's planned 36 months is above that.
Counting every sponsor, half of 209 studies reached it within 24 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →